• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

AXIM to Present at Annual Symposium in The Netherlands

June 28, 2018

 

NEW YORK, June 28, 2018 -- /D.M.O. Newswire/ -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company will be attending as a sponsor. at the 28th Annual International Cannabinoid Research Society (ICRS) Symposium taking place in Leiden, The Netherlands from June 30 – July 5, 2018. AXIM’s Advisory Board Member and Chairman of Pharmacology at the University of Wageningen, Professor Dr. Renger Witkamp, will present the results from its phase IIA clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew® Plus 50 mg cannabidiol (CBD) functional, controlled-release chewing gum.

 

“We are always excited for opportunities like this prestigious, scientific symposium to showcase and educate audiences on AXIM’s ongoing research with cannabinoid molecules and their potential for the treatment of various indications, in this case our IBS clinical trial results,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “We look forward to sharing our accomplishments within the cannabinoid research community and learning about other innovative research being done in the industry.”

 

The International Cannabinoid Research Society (ICRS) is a non-political organization dedicated to scientific research regarding cannabinoids, ranging from biochemical, chemical, and physiological studies of the endogenous cannabinoid system to studies of the abuse potential of recreational cannabis. In addition to acting as a source for impartial information on cannabis and cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their clinical studies.

 

IBS is the most common gastrointestinal disorder with a prevalence worldwide ranging from 9-23% of the general population. Complaints include abdominal discomfort or pain and altered bowel habits. Although the condition is not life-threatening, it strongly impairs quality of life and up to now there is no cure for IBS currently on the market.

 

AXIM® Biotech is a gold sponsor of the 28th annual ICRS Symposium. AXIM representatives will be available onsite to discuss the company’s current research and product pipeline, as well as potential business and investment prospects at the conference.

 

For more information about the ICRS and the upcoming 2018 Symposium, please visit http://icrs.co/.

 

About AXIM® Biotechnologies
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew+®, a CBD-based controlled release chewing gum, CanChew+ 50®, containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx®, a combination CBD/THC gum that will undergo clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. AXIM has several products developed or in developmental stage for treatment and/ or prevention of multiple conditions and symptoms. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

 

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

 

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.